New opioid withdrawal drug shows promise in tiny early trial
NCT ID NCT04316559
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested a new drug called TRV734 in 5 adults with opioid-use disorder who were already on methadone. The goal was to see if TRV734 could relieve withdrawal symptoms with fewer side effects than a standard opioid like oxycodone. Participants stayed in a residential unit and received either TRV734, oxycodone, or a placebo on different days. The trial was terminated early, so results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TRV734 (biased opioid agonist)
What this could lead to
If successful, TRV734 could offer a new option to manage opioid withdrawal with fewer side effects than current treatments.
What could go wrong
This was a very small pilot study (only 5 participants) that was terminated early, so results are limited and may not apply broadly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institute on Drug Abuse (NIDA)
Baltimore, Maryland, 21224, United States